Data from ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia
Li Zhu,Qin Li,Stephen H.K. Wong,Min Huang,Brianna J. Klein,Jinfeng Shen,Larissa Ikenouye,Masayuki Onishi,Dominik Schneidawind,Corina Buechele,Loren Hansen,Jesús Duque-Afonso,Fangfang Zhu,Gloria Mas Martin,Or Gozani,Ravindra Majeti,Tatiana G. Kutateladze,Michael L. Cleary
DOI: https://doi.org/10.1158/2159-8290.c.6546333.v1
2023-01-01
Abstract:AbstractNumerous studies in multiple systems support that histone H3 lysine 36 dimethylation (H3K36me2) is associated with transcriptional activation; however, the underlying mechanisms are not well defined. Here, we show that the H3K36me2 chromatin mark written by the ASH1L histone methyltransferase is preferentially bound in vivo by LEDGF, a mixed-lineage leukemia (MLL)–associated protein that colocalizes with MLL, ASH1L, and H3K36me2 on chromatin genome wide. Furthermore, ASH1L facilitates recruitment of LEDGF and wild-type MLL proteins to chromatin at key leukemia target genes and is a crucial regulator of MLL-dependent transcription and leukemic transformation. Conversely, KDM2A, an H3K36me2 demethylase and Polycomb group silencing protein, antagonizes MLL-associated leukemogenesis. Our studies are the first to provide a basic mechanistic insight into epigenetic interactions wherein placement, interpretation, and removal of H3K36me2 contribute to the regulation of gene expression and MLL leukemia, and suggest ASH1L as a novel target for therapeutic intervention.Significance: Epigenetic regulators play vital roles in cancer pathogenesis and represent a new frontier in therapeutic targeting. Our studies provide basic mechanistic insight into the role of H3K36me2 in transcription activation and MLL leukemia pathogenesis and implicate ASH1L histone methyltransferase as a promising target for novel molecular therapy. Cancer Discov; 6(7); 770–83. ©2016 AACR.See related commentary by Balbach and Orkin, p. 700.This article is highlighted in the In This Issue feature, p. 681